N-Acetylcysteine enhances the action of anti-inflammatory drugs as suppressors of prostaglandin production in monocytes. by Hoffer, Erica et al.
N-Acetylcysteine enhances the
action of anti-inflammatory drugs
as suppressors of prostaglandin
production in monocytes
Erica Hoffer1,3,CA, Yelena Baum1 and
A. Menahem Nahir2,3
1Israel Poison Information Center, Toxicology and
Clinical Pharmacology Laboratory, and 
2Department
of Rheumatology, Rambam Medical Center, Haifa
31096, Israel; and 
3Faculty of Medicine, Technion
Institute of Technology, Haifa, Israel
CACorresponding Author
Tel: +972 4 8543440;
Fax: +972 4 8542092
E-mail: erica@rambam.health.gov.il
THE anti-inflammatory  effect  of  non-steroidal  anti-
inflammatory  drugs  (NSAIDs)  is  associated  with
inhibition of cyclooxygenase (COX), the rate-limiting
enzyme  responsible  for  the  synthesis  of  prosta-
glandins. Since oxygen free radicals can act as second
cellular  messengers,  especially  to  modulate  the
metabolism  of  arachidonic  acid  and  the  prosta-
glandin  tract,  it  seems  plausible  that  antioxidants
might  affect  the  production  of  prostaglandin  by
activated cells. This research is focused on the effect
of  the  antioxidant  N-acetylcysteine  (NAC)  on  the
inhibition of prostaglandin E2 formation in activated
monocytes by specific and non-specific COX inhibi-
tors. We found that lipopolysaccharide-induced pros-
taglandin E2 formation was significantly reduced by
rofecoxib and by diclofenac, two NSAIDs. Addition of
NAC to each of these drugs enhanced the effect of the
NSAIDs. These results suggest that one might expect
either a potentiation of the anti-inflammatory effect
of COX inhibitors by their simultaneous administra-
tion with NAC, or obtaining the same anti-inflamma-
tory at lower drug levels.
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Introduction
The biochemical basis of the process of inflammation
is the formation of prostaglandins and leukotrienes by
two chains of reactions stemming  from  a common
precursor  –  the  arachidonic  acid.  In  the  case  of
prostaglandins  the  cyclooxygenase  (COX)  enzyme
system  plays  a  pivotal  role,  while  in  the  case  of
leukotrienes it is the lipoxygenase system.
Non-steroid anti-inflammatory drugs (NSAIDs) are
the first line of choice in the treatment of inflamma-
tory joint diseases. Inhibition of COX and therefore of
prostaglandin production is the common mechanism
of action of NSAIDs. It is known today that COX exists
in two isoforms: COX-1 is present in the endothelium,
stomach and kidney, and COX-2 is induced in vivo at
inflammatory sites.1 These findings have lead to the
development  of  COX-2-specific  drugs  that  alleviate
the  pain  caused by  inflammation  of  the  joints but
have  a  lower  gastrointestinal  toxicity,  which  it  is
usually associated with COX inhibition.
Antioxidants  have  already  been  investigated  as
candidates  in  the  treatment  of  inflammatory  joint
diseases. Kroger  et al.2 showed that the inhibitory
effect of nicotinamide upon collagen-induced arthritis
in mice is enhanced by N-acetylcysteine (NAC). High
doses  of  vitamin  E  were  found  effective  when
compared  with  diclofenac  in  chronic  polyarthritis
patients.3 Also,  in  certain  cells  like  mesangial4 or
colorectal  cells,5 antioxidants  reduce  COX-2
expression.
Abate et al.6 addressed specifically the synergism
between aspirin and vitamin E in reducing lipopoly-
saccharide  (LPS)-induced  prostaglandin  E2 (PGE2)
production in a macrophage cell line. They found that
the combined inhibition of these two factors is larger
than  that  of  their  sum.  In  the  present  paper,  we
consider  two  newer  drugs;  the  non-specific  COX
inhibitor diclofenac and the specific COX-2 inhibitor
rofecoxib, both in conjunction with NAC.
Methods
Materials
LPS  from  Escherichia  coli (serotype  type  026B6),
NAC,  diclofenac  sodium  salt  and  Histopaque-1077
were purchased from Sigma Chemical Co. (St Louis,
MO,  USA).  Dulbecco’s  phosphate-buffered  saline
(PBS), RPMI medium 1640 and fetal calf serum (FCS)
were purchased from Biological Industries (Bet Hae-
mek, Israel). Rofecoxib (Vioxx) was a gift from Merck
Sharp & Dohme (Petach Tikwa, Israel). The enzyme-
linked immunosorbent assay (ELISA) kit for PGE2 was
purchased  from  R&D  systems  (Minneapolis,  MN,
USA).
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Blood  was  collected by  venipuncture  from  healthy
volunteers  who  did  not  take  any  drugs.  Twenty
milliliters of heparinized blood (10U of heparin/ml of
blood) were layered carefully on an equal volume of
Histopaque-1077  in  a 50ml conical centrifuge  tube
and the suspension was centrifuged for 30min, 700 ´
g at room temperature. The mononuclear cell  layer
between  the  plasma  and  Histopaque  layers  was
collected and washed three times with Dulbecco PBS
(by centrifugation for 5min at 4°C). The cells were
resuspended in a known volume of RPMI 1640. The
cells were counted and their viability was determined
by Trypan blue exclusion. The purity of preparation
was  assessed  to  be  98–99%  mononuclear  cells,  of
which 10–12% were monocytes.
Cell incubation
The cells were placed (1 million/ml of mononuclear
cells) in a 24-well  dish, 1ml of suspension in each
well, and pre-incubated in a humidified incubator at
37°C  and  5%  CO2 for  2h  in  RPMI  1640  that  also
contained 5% FCS. The cells were washed three times
with Dulbecco PBS pre-warmed to 37°C to discard
unattached cells. Inspection of the nucleus morphol-
ogy  revealed  that  98–99%  of  cells  isolated  in  this
manner were monocytes.
Measurement of PGE2 accumulation
The plated cells were subsequently treated with LPS
(10mg/ml) and a combination of drugs with/without
NAC  in  RPMI  1640  with  10%  FCS  for  18h.  The
supernatant was then collected, centrifuged and PGE2
was determined with an ELISA kit, according to the
manufacturer’s instructions.
Statistics
Parallel experiments with monocytes from the same
donor  were  carried  out  with  and  without  anti-
oxidants. The results were compared by means of the
Wilcoxon paired test.
Results
Effect  of  diclofenac  and  rofecoxib  on  LPS-induced
formation of PGE2
Since it was shown that the LPS-inducible cycloox-
ygenase in macrophages is COX-2,7 we might assume
that in the present experiments the measured PGE2
production  represents  the  COX-2  activity  of  these
cells.  Table  1  presents  the  effect  of  diclofenac  at
concentrations  of  0.01  and  0.001mM  and  that  of
rofecoxib at 0.01 and 0.001mM on PGE2 production
by LPS-activated monocytes. The results are expressed
as percent inhibition: % inhibition = [1 – PGE2 (with
NSAIDs)/PGE2 (without NSAIDs)].
It is apparent that both NSAIDs inhibit  the PGE2
production, diclofenac being the more potent inhib-
itor. The effect of diclofenac only on PGE2 production
was investigated in mononuclear cells,8 and an IC50
(the concentration required for 50% inhibition)  value
of 0.03mM was obtained for COX-2 inhibition. In our
system, which is different from that of Laufer et al.,8
the IC50 values for diclofenac and for rofecoxib were
0.0035 and 0.0085mM, respectively.
The effect of various NSAIDs on inhibition of PGE2
production was carried out in a whole blood assay9
where IC50 values of 0.038 and 0.84mM for diclofenac
and  rofecoxib,  respectively,  were  reported. To  our
knowledge, the present research is the first in which
a comparison between a specific and a non-specific
COX inhibitor with respect to PGE2 production has
been carried out in mononuclear cells.
Effect of NAC on diclofenac and rofecoxib-induced
inhibition of PGE2 formation
It is apparent from Fig. 1 that addition of 1 mM NAC
to the incubation mixture containing either diclofe-
nac  or  rofecoxib  enhanced  the  inhibition  of  PGE2
formation induced by these drugs. The effect is more
prevalent when the NSAID-induced inhibition is low,
for example in the case of 0.001mM diclofenac. It is
worthwhile to mention that 1 mM NAC alone depres-
ses also prostaglandin production by 55.5%.
In the present experimental system, we found that
vitamin E has no effect of on the inhibitory action of
diclofenac and rofecoxib (results not reported).
Discussion
A synergistic effect of sulfosalicylic acid and vitamin E
on stimulated PGE2 release in a macrophage cell line
(J774.1A) was recently reported by Abate et al.6 In
that work, a  relative high  concentration of sulfosa-
licylic  acid  (1mM)  inhibited  the  LPS-induced  PGE2
release  by  70%;  addition  of  300mM  vitamin  E
enhanced this inhibition to 90%. This trend could be
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Table 1. Per cent inhibition by diclofenac and rofecoxib of
LPS-induced PGE2 formation in monocytes
Concentration (mM) % inhibition
Diclofenac Rofecoxib
0.001 39.0 ± 2.7
0.01 79.4 ± 0.7 55.5 ± 1.86
0.1 70.5 ± 1.4explained  by  COX-2  expression  experiments  only
when  the  sulfosalicylic  acid  and  the  vitamin  E
concentrations  were  both  300mM.  Since  in  the
present experimental system no enhanced inhibition
of  PGE2 formation  was  observed  when  NAC  was
replaced by vitamin E, we conclude that the inhibi-
tory effect of NAC on PGE2 formation is not related to
its antioxidant properties. Abate et al.,6 who could
not  observe  a  synergistic  effect  on  the  effect  of
sulfosalicylic  acid when vitamin E  was replaced by
another antioxidant, namely vitamin C, confirm this
thesis.
We  demonstrated in  previous  research  that  NAC
exerts its inhibitory action on leukotriene production
by alveolar macrophages by suppressing arachidonic
acid formation (the PLA2 enzyme system).10 Since it
was  reported11 that monocytes release arachidonic
acid upon  stimulation  with  a  variety  of  soluble  or
particulate agents, our results could be explained by
an effect  of  NAC on  arachidonic acid formation  in
these cells.
As we have shown that the NSAID-induced inhibi-
tion of prostaglandin formation is enhanced by NAC,
one might expect that in vivo experiments with this
combination of agents will exhibit either a potentia-
tion of the anti-inflammatory effect of NSAIDs or an
anti-inflammatory effect at lower NSAID drug levels.
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FIG. 1. The effect of 1 mM NAC on the diclofenac-induced and rofecoxib-induced inhibition of PGE2 formation in activated
monocytes. * p<0.05 for % inhibition (NSAID + NAC) versus % inhibition (NSAID), Wilcoxon paired test. All data shown are
mean ± SEM of number of observations (n). Number of observations: 0.01µM diclofenac, n = 9; 0.001µM diclofenac, n = 6;
0.1µM rofecoxib and 0.01µM rofecoxib, n = 8.